Ruserontinib

N/A

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameRuserontinib
Drug Alias NameSKLB-1028
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsTyrosine-protein kinase receptor FLT3 inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsBcr-Abl tyrosine kinaseEpidermal growth factor receptor erbB1Tyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsSolid tumoursLeukemia, Promyelocytic, AcuteLeukemia, Myeloid, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSichuan UniversityCSPC Pharmaceutical Group Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdSichuan UniversityCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLeukemia, Promyelocytic, AcuteLeukemia, Myeloid, Acute +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A